PPT-CROI 2015: What’s New in Hepatitis?

Nina Kim MD Associate Professor of Medicine Division of Allergy amp Infectious Diseases University of Washington No financial conflicts of interest ION4 LedipasvirSofosbuvir for 12 weeks. Strategies To Identify and Advance PWID HCV Patient Care. Linkage to C Care Program. . Imtiaz Alam, M.D.. Medical Director, Austin Hepatitis Center. Medical Director, . HepCare. Specialty Pharmacy. New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD AIDS Research Consortium of Atlanta Follow me on Twitter @ drmt Financial Relationships With Commercial Entities Dr Thompson's institution has received grants for research from Bristol-Myers Squibb, CytoDyn, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, Oluwatoyin ( . Toyin. ) Adeyemi, MD. Director, CORE Viral hepatitis Clinic. Senior director for HIV services, Cook County Health . Triple Threat 11: HIV, HCV & . Opiods. Dusable. Museum , June 25, 2019. reports*, . by risk . exposure/behavior† . — United States, 2015. Source. : CDC, . National Notifiable Diseases Surveillance System (NNDSS). *A total of 2,436 case reports of acute hepatitis C were received in 2015. . 80 dress for CorEmine Parlak MD, Atatürk University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Erzurum, Turkey eparlak1@yahoo.com Hepatitis delta virus (HDV) i 80 dress for CorEmine Parlak MD, Atatürk University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Erzurum, Turkey eparlak1@yahoo.com Hepatitis delta virus (HDV) i Résumé scientifique des principales études cliniques présentées à la CROI 2019. CAHR is pleased to provide this scientific summary of the major clinical studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019). The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV. This presentation was made possible with the support of an educational grant from ViiV Healthcare.. Prediction. . of . events. . after. ART. initiation. INSTI . and IRIS ?. Test and . Treat. Same. Day. Switch DTG/ABC/3TC. to BIC/F/TAF. Miscellaneous. ART. Test and Treat the Same Day - Is this feasible ?. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. March 5, 2015. ECHO CROI Reviews 2015. 3/5/15. 3/12/15. 3/19/15. Brian Wood: . Primary Care. Shireesha Dhanireddy. Robert Harrington. March 17, 2014. No financial conflicts of interest. Outline. Treatment Studies. Tenofovir. . alafenamide. (TAF) in a single-tablet regimen in initial HIV-1 infection . Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Jeffrey Lennox, MD. Professor of Medicine. Emory University. Atlanta. , Georgia. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Alafenamide. in Renal Impairment. A Pozniak. 1. , J Arribas. 2. , . SK Gupta. 3. , . FA Post. 4. , A Avihingsanon. 5. , . G Crofoot. 6. , . K Lichtenstein. 7. , M Ramgopal. 8. , P Chetchotisakd. 9. , MW Fordyce. AND OPPORTUNISTIC INFECTIONS. (CROI 2020). BOSTON| 8-11 MARCH 2020. Faculty. Pedro . Cahn. , Buenos-Aires, Argentina. Anton . Pozniak. , London, UK. François . Raffi. , Nantes, France. This presentation is made in complete editorial freedom .